To complement previous study results, the present study aimed not only to evaluate the analytical performance of the Oncomine Lung cfDNA Assay compared with the cobas® EGFR Mutation Test v2 but also the consistency of EGFR mutations in primary tumor tissues and plasma samples. The gene discussed is EGFR; the disease is neoplasm.